Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MicroRNA-29: A Crucial Player in Fibrotic Disease.

Literature DB >> 28130757

MicroRNA-29: A Crucial Player in Fibrotic Disease.

Zhenjun Deng¹, Yongjing He^1,2, Xujuan Yang¹, Hang Shi¹, Ao Shi³, Lechun Lu^4,5, Li He⁶.

Abstract

Fibrosis is a common pathological state characterized by the excessive accumulation of extracellular matrix components, but the pathogenesis of the disease is still not clear. Previous studies have shown that microRNA-29 (miR-29) can play pivotal roles in the regulation of a variety of organ fibrosis, including cardiac fibrosis, hepatic fibrosis, lung fibrosis, systemic sclerosis, and keloid. In this review, we outline the structure, expression, and regulation of miR-29 as well as its role in fibrotic diseases.

Entities: Disease Gene

Mesh：

Substances：

Year: 2017 PMID： 28130757 DOI： 10.1007/s40291-016-0253-9

Source DB: PubMed Journal: Mol Diagn Ther ISSN： 1177-1062 Impact factor: 4.074

72 in total

1. Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells.

Authors: Jiang Li; Yifei Zhang; Ramalinga Kuruba; Xiang Gao; Chandrashekhar R Gandhi; Wen Xie; Song Li
Journal: Mol Pharmacol Date: 2011-04-21 Impact factor: 4.436

Review 2. The widespread regulation of microRNA biogenesis, function and decay.

Authors: Jacek Krol; Inga Loedige; Witold Filipowicz
Journal: Nat Rev Genet Date: 2010-07-27 Impact factor: 53.242

Review 3. Posttranscriptional regulation of microRNA biogenesis in animals.

Authors: Haruhiko Siomi; Mikiko C Siomi
Journal: Mol Cell Date: 2010-05-14 Impact factor: 17.970

4. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors: Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal: Blood Date: 2010-10-28 Impact factor: 22.113

5. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR.

Authors: J Robin Lytle; Therese A Yario; Joan A Steitz
Journal: Proc Natl Acad Sci U S A Date: 2007-05-29 Impact factor: 11.205

6. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells.

Authors: Tomohiro Ogawa; Masashi Iizuka; Yumiko Sekiya; Katsutoshi Yoshizato; Kazuo Ikeda; Norifumi Kawada
Journal: Biochem Biophys Res Commun Date: 2009-11-12 Impact factor: 3.575

7. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation.

Authors: Kristin Dawson; Reza Wakili; Balázs Ordög; Sebastian Clauss; Yu Chen; Yuki Iwasaki; Niels Voigt; Xiao Yan Qi; Moritz F Sinner; Dobromir Dobrev; Stefan Kääb; Stanley Nattel
Journal: Circulation Date: 2013-03-04 Impact factor: 29.690

8. Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis.

Authors: Virender Kumar; Goutam Mondal; Rinku Dutta; Ram I Mahato
Journal: Biomaterials Date: 2015-10-23 Impact factor: 12.479

9. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation.

Authors: Yi Fang; Xiaofang Yu; Yong Liu; Alison J Kriegel; Yanyan Heng; Xialian Xu; Mingyu Liang; Xiaoqiang Ding
Journal: Am J Physiol Renal Physiol Date: 2013-03-06

Review 10. MicroRNAs in fibrosis: opportunities and challenges.

Authors: Steven O'Reilly
Journal: Arthritis Res Ther Date: 2016-01-13 Impact factor: 5.156

20 in total

Review 1. Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.

Authors: Rajendra Awasthi; Michael John Rathbone; Philip Michael Hansbro; Mary Bebawy; Kamal Dua
Journal: Drug Deliv Transl Res Date: 2018-02 Impact factor: 4.617

2. The integrative regulatory network of circRNA and microRNA in keloid scarring.

Authors: Jingpei Shi; Shuluan Yao; Pan Chen; Yuan Yang; Mengjiao Qian; Yi Han; Nan Wang; Yu Zhao; Yongjing He; Lechun Lyu; Di Lu
Journal: Mol Biol Rep Date: 2019-10-14 Impact factor: 2.316

3. Transcriptional regulatory model of fibrosis progression in the human lung.

Authors: John E McDonough; Farida Ahangari; Qin Li; Siddhartha Jain; Stijn E Verleden; Jose Herazo-Maya; Milica Vukmirovic; Giuseppe DeIuliis; Argyrios Tzouvelekis; Naoya Tanabe; Fanny Chu; Xiting Yan; Johny Verschakelen; Robert J Homer; Dimitris V Manatakis; Junke Zhang; Jun Ding; Karen Maes; Laurens De Sadeleer; Robin Vos; Arne Neyrinck; Panayiotis V Benos; Ziv Bar-Joseph; Dean Tantin; James C Hogg; Bart M Vanaudenaerde; Wim A Wuyts; Naftali Kaminski
Journal: JCI Insight Date: 2019-11-14

MicroRNA-29: A Crucial Player in Fibrotic Disease.

1. Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells.

Review 2. The widespread regulation of microRNA biogenesis, function and decay.

Review 3. Posttranscriptional regulation of microRNA biogenesis in animals.

4. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

5. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR.

6. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells.

7. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation.

8. Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis.

9. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation.

Review 10. MicroRNAs in fibrosis: opportunities and challenges.

Review 1. Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.

2. The integrative regulatory network of circRNA and microRNA in keloid scarring.

3. Transcriptional regulatory model of fibrosis progression in the human lung.

4. A therapeutic approach towards microRNA29 family in vascular diabetic complications: A boon or curse?

5. miRNA-29 aggravates myocardial infarction via inhibiting the PI3K/mTOR/HIF1α/VEGF pathway.

Review 6. MicroRNA-21 in Skin Fibrosis: Potential for Diagnosis and Treatment.

7. Integrated Interaction Network of MicroRNA Target Genes in Keloid Scarring.

Review 8. Role of the microRNA-29 family in myocardial fibrosis.

9. Adiponectin inhibits hepatic stellate cell activation by targeting the PTEN/AKT pathway.

Review 10. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches.